CONSENSYS
17.11.2021 16:17:07 CET | Business Wire | Press release
Today, ConsenSys announced the close of a $200 million USD financing round, bringing its valuation to $3.2 billion USD. New investors Marshall Wace, Third Point, ParaFi Capital, and Think Investments contributed to the round alongside new partners that include Dragonfly Capital, Electric Capital, Spartan Group, DeFiance Capital, Animoca Brands, Coinbase Ventures, and HSBC. Sullivan & Cromwell LLP acted as ConsenSys’ legal advisor in this transaction.
ConsenSys’ mission is to unlock the collaborative power of communities by making Web3 universally easy to use, access, and build on. MetaMask is the primary way a global user base of approximately 21 million monthly active users — a 38x increase from 2020 — interacts with a universe of approximately 3,700 unique Web3 applications. Web3 allows creators to capture the true value of their work and communities to organize in real time, largely unfettered by borders. These applications include NFT marketplaces, play-to-earn games, decentralized autonomous organizations (DAOs), decentralized finance (DeFi) applications, and metaverse worlds.
As the leading self-custodial wallet, MetaMask acts as a digital authority manager for Web3 — only permitting websites and apps to access data that a user consents to. MetaMask’s in-app swap feature has enabled more than $10 billion USD in peer-to-peer token swapping. Additionally, MetaMask now supports Ethereum-compatible Layer 2 networks such as Polygon, Optimism, Arbitrum, zkSync, BSC, Celo, Avalanche, and NEAR/Aurora, which represents more than 90% of global smart contract network volume. An institution-compliant version of Metamask, MetaMask Institutional integrates custody and compliance solutions that enable organizations to access and engage in DeFi. ConsenSys is also ramping up its efforts to drive NFT adoption for artists, content creators, brands, rights owners, game publishers, and leagues.
ConsenSys’ developer tools and infrastructure are anchored by Infura, which is used by 350k developers , including MetaMask and leading DeFi and NFT platforms. Developers choose Infura because of its industry leading scale and performance, best-in-class documentation, and resources to help developers spend less time on infrastructure and more time building. ConsenSys is increasingly integrating its other products with Infura to support the entire development lifecycle, such as Truffle (4.7 million developers) for writing and testing smart contracts, Diligence for securing smart contracts with hands-on code audits and automated testing tools, and Customer Success for tech support. ConsenSys Quorum Blockchain Service offers a fully managed Ethereum blockchain service to enterprises. ConsenSys Quorum is already in use by 10 different Central Bank Digital Currency projects around the world. ConsenSys’ protocol and R&D engineers are main drivers of Ethereum’s upcoming merge which will bring the more energy efficient and scalable Proof of Stake consensus system to Ethereum.
Funding will support the rapid expansion of MetaMask and Infura’s industry leading products as well as the addition of 400 new roles across its products and services.
Joseph Lubin, Founder & CEO of ConsenSys and Co-creator of Ethereum said, “The Age of Silos and Trusted Third Parties (h/t @punk6529) is giving way to the Age of Community and Collaboration enabled by an automated, objective, trust foundation and a decentralized finance ecosystem. The paradigm shift to a world running on decentralized protocols is in full gear. The pace of adoption is now so rapid that we’ve more than doubled many of our core KPIs since this deal was struck over the summer. We are honored to partner with some of the top financial and strategic investors from both traditional and next generation economies to accelerate the realization of Web3. As our technology crosses into the mainstream, we are already seeing the transformation of how larger and larger cohorts of builders, users, artists, and enterprises live and work.”
Amit Rajpal, Partner and CEO Asia at Marshall Wace said, "We are excited to be investing in ConsenSys. The consumer, developer, and enterprise ecosystems for Defi and NFT applications are building exponentially and blockchain technology companies, like ConsenSys, which have multi-faceted technology offerings are in position to be the access point to this universe. We particularly look forward to working with Joe and his team to enhance their presence in the Asian region where adoption rates are rising rapidly."
Daniel S. Loeb, CEO and Founder of Third Point LLC said, “ConsenSys’ MetaMask wallet and other tools offer a unique platform for consumers, enterprises, and developers to engage, build, and create on the decentralized web. We are pleased to partner with ConsenSys to help unlock the unlimited potential of Web 3.0.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom